clinicopathological conference on thyroid eye disease
DESCRIPTION
for medical students and doctorsTRANSCRIPT
![Page 1: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/1.jpg)
IN THE NAME OF ALLAH, THE MOST BENEFICIENT ,
THE MOST MERCIFUL .
![Page 2: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/2.jpg)
CASE PRESENTATION:THYROID EYE DISEASE
• SUPERVISED BY, DR. WASEEM AHMED
KHAN
DOMS,MCPS,FCPS,FRCS(UK)
Assistant Professor MIMC
• PRESENTED BY, TASHFEEN BASHARAT HINA BATOOL RABYIA ASHRAF BUSHRA ALI RABIA FAROOQ ZAKIA SULTANA
![Page 3: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/3.jpg)
![Page 4: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/4.jpg)
DEMOGRAPHICS
Name:Imran sharifSex:MaleAge:26 yrsResident of:MirpurMarital status:MarriedEducation:MBAPresented to: OPD
![Page 5: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/5.jpg)
PRESENTING COMPLAINTS
• Heaviness and pain in both eyes 2yrs back• Right sided headache 2yrs back
![Page 6: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/6.jpg)
HISTORY OF PRESENT ILLNESS
• Pt. was in usual state of health 2yrs back when he gradually developed heaviness and pain in both eyes with right sided headache in temporal region.After a couple of weeks he felt bulging of both eyes as well with bilateral diplopia on side gaze, condition was progressive in nature , there were no aggrevating & relieving factors,it was not associated with redness,discharge,photophobia and change in vision,he consulted an ophthalmologist at SHIFA INTERNATIONAL hospital islamabad,where he was dignosed as a case of proptosis and was prescribed oral steroids along with topical lubricants
![Page 7: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/7.jpg)
HISTORY OF PRESENTING ILLNESS
• He was also reffered to medical specialist to rule out thyroid disease as he was also complaining of frequent vomitting,loss of appetite,palpitations and diarrhea,where he was examined and investigated properly.He was dignosed hyperthyroidism,anti thyroid treatment was started.He took it for 2yrs but left it one month ago without the advice of doctor.Now from last 3 to 4 days he is again complaining of bulging and pain of both eyes along with diplopia for which he is taking eye drops.
![Page 8: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/8.jpg)
PAST OPTHALMIC HISTORY
![Page 9: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/9.jpg)
PAST OPHTHALMIC HISTORY
• He is myopic from last few years and he is using spectacles of 1.5 diopters in both eyes for myopic correction.
• No other significant past ophthalmic history was found.
![Page 10: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/10.jpg)
SYSTEMIC HISTORY
![Page 11: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/11.jpg)
SYSTEMIC HISTORY
• General health:• Loss of appetite• Loss of weight• Lack of energy• Normal sleep
![Page 12: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/12.jpg)
• CARDIO VASCULAR SYSTEM:
• PALPITATIONS PRESENT• NO BREATHLESSNESS, CHEST
PAIN AND EDEMA FEET
![Page 13: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/13.jpg)
SYSTEMIC HISTORY
• RESPIRATORY SYSTEM• No cough, sputum, hemoptysis,
breathlessness, wheezing and chest pain• ALIMENTARY SYSTEM:• Vomiting ( containing food particles)• Diarrhea present• No nausea, abdominal pain, dysphagia, heart
burn, constipation, hematemesis, melena and jaundice
![Page 14: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/14.jpg)
SYSTEMIC HISTORY
• URINARY SYSTEM:• No pain in flanks, dysuria, hematuria,
frequency of micturation, polyuria, oliguria, nocturia, nausea and vomiting
• NERVOUS SYSTEM:• Right sided headache in temporal region• Bilateral Diplopia present on side gaze• No numbness, giddiness, fits, visual loss
![Page 15: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/15.jpg)
• ENDOCRINE SYSTEM• Heat intolerance present• Weight loss present• Palpitations present• No polyuria, polyphagia, polydypsia• MUSCULOSKELETAL SYSTEM:
no joint pain, stiffness, swelling and restriction of movment.
• SKIN• No Rash, itch, coloured spots
![Page 16: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/16.jpg)
PAST MEDICAL & SURGICAL HISTORY
![Page 17: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/17.jpg)
PAST MEDICAL AND SURGICAL HISTORY:
Appendisectomy was done at the age 17 yrs.
No other significant past medical and
surgical history .
![Page 18: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/18.jpg)
![Page 19: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/19.jpg)
PERSONAL HISTORY:
He is married for last 4 yrs having 2 children ( boys). HE IS A NON SMOKER. Not addicted to any drug and his sleep is
normal.
![Page 20: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/20.jpg)
FAMILY HISTORY
![Page 21: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/21.jpg)
FAMILY HISTORY
Father is diabetic for last 20 years and is taking oral anti diabetic treatment.
Mother died of heart attack 1 yr back.
No other family history of Proptosis, hyper thyriodism, hypertension,
tuberculosis, asthma and cancer was present.
![Page 22: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/22.jpg)
SOCIOECNOMIC HISTORY
![Page 23: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/23.jpg)
SOCIO ECONOMIC HISTORY:
• He runs his own business( show room of bikes),
• living in his own house,• financially stable.
![Page 24: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/24.jpg)
![Page 25: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/25.jpg)
Examination
![Page 26: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/26.jpg)
EXAMINATION
• 1) SYSTEMIC
• 2) OCULAR
![Page 27: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/27.jpg)
SYSTEMIC EXAMINATION• GENERAL PHYSICAL EXAMINATION• Pateint was sitting comfortably on chair well
oriented in time and space.• VITALS• Pulse :-120 beats/min• B.P :-120/80 mmHg• Respiratory Rate:- 16breaths/min• Temperature:- 37C
![Page 28: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/28.jpg)
GENERAL PHYSICAL EXAMINATION
• FINGERS no deformity
• PALM
palmar erythema +ve sweating
+ve
![Page 29: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/29.jpg)
GENERAL PHYSICAL EXAMINATION
• FACE Puffiness Negative Proptosis Positive No other deformity
![Page 30: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/30.jpg)
THYROID EXAMINATION
• INSPECTION:• PALPATION:• AUSCULTATION• PEMBERTON SIGN
• NO VISIBLE SWELLING• NOT PALPABLE• NO BRUIT• ABSENT
![Page 31: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/31.jpg)
GENERAL PHYSICAL EXAMINATION• Neck veins No pulsation JVP normal
• AXILLA Lymph Nodes not palpable• GROIN Lymph nodes not palpable• FEET Clubbing koilonychnia cynosis Not Significant loss of hair Edema
![Page 32: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/32.jpg)
SYSTEMIC EXAMINATION
• CVS No significant findings• G.I.T No significant findings• C.N.S No significant findings• Respiratory No significant findings
![Page 33: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/33.jpg)
OCULAR EXAMINATION
![Page 34: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/34.jpg)
FUNCTIONAL EXAMINATION :-
VISUAL ACUITY: 6/18 both eyes with
spectacles 6/6 both eyes
COLOUR VISION: normal
VISUAL FIELD: normal
![Page 35: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/35.jpg)
PROPTOSIS EXAMINATION
• INSPECTION • Bilateral bulging of eyes( front & side views) • SWALLOW TEST: NEGATIVE
• PALPATION • BILATERAL AXIAL PROPTOSIS 4-5 mm in both eyes • SUPERFICIAL PALPATION:• NORMAL ORBITAL RIM WITHOUT TENDERNESS• DEEP PALPATION:• NO ORBITAL MASS ON DEEP PALPATION
![Page 36: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/36.jpg)
EXAMINATION OF PROPTOSIS• EXTRA OCULAR
MOVEMENTS• ABDUCTION & ELEVATION
DEFECIT & DIPLOPIA IN SIDE GAZE
• RETROPULSION: POSITIVE IN BOTH EYES
• NO LYMPHYADENOPATHY IN ADJOINING AREAS
• AUSCULTATION:• BRUIT: ABSENT
![Page 37: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/37.jpg)
PROPTOSIS EXAMINATION
• Signs checked for bilateral buldging of eyes • Dalrymples Sign:- +ve (This is stare due to retraction of upper lid )• Von Graefes Sign:- +ve (upper lid lags on downward movement of
eyeball )
![Page 38: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/38.jpg)
OCULAR EXAMINATION
• EYELID • Skin :- Normal on both sides• Lid Margin:- BILATERAL Upper lid retracted • Bilateral Lid lag• Eyelashes:- Normal on both sides
• INTER PALPEBRAL FISSURE WIDTH • Pateint value :- 13mm• Normal range :- 9-11mm
• LACRIMAL SYSTEM • Drainage system :-Normal • Regurgitation test –ve
![Page 39: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/39.jpg)
OCULAR EXAMINATION
• CONJUCTIVA :- Normal• LIMBUS :- Normal• CORNEA :- Clear • ANTERIOR CHAMBER : Normal
![Page 40: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/40.jpg)
OCULAR EXAMINATION
• IRIS :-Normal• PUPIL:- Round and reactive to light Diameter :- 3mm• Light reflex :- Normal• Indirect light reflex :- normal • LENS :- clear no opacities found • VITREOUS :- red reflex was intact
![Page 41: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/41.jpg)
OCULAR EXAMINATION
• RETINA :- Slit lamp :- Mild disc
pallor ( both eyes) MEASUREMENT OF IOP
BY APPLANATION TONOMETRY
Pateint value :- 16mmHg both eyes
(Normal 10-21mmHg)
![Page 42: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/42.jpg)
DIFFERENTIAL DIAGNOSIS
• THYROID EYE DISEASE• IDIOPATHIC ORBITAL INFLAMMATORY
DISEASE
![Page 43: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/43.jpg)
![Page 44: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/44.jpg)
INVESTIGATIONS
![Page 45: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/45.jpg)
BASELINE INVESTIGATIONS
• COMPLETE BLOOD PICTURE• Hb === 12g/dl• WBC== 8.0 × 10 ( per cubic mm of blood).• PLATLET COUNT== 274 × 10 ( per cubic mm of
blood)
![Page 46: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/46.jpg)
BASELINE INVESTIGATIONS
• BLOOD SUGAR RANDOM=== 12Omg/dl• TOTAL CHOLESTROL === 167mg/dl• TRIGLYCERIDE === 139mg/dl
![Page 47: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/47.jpg)
THYROID PROFILE
• Following investigations were done for thyroid function:
• Total T3• Total T4• TSH• Thyroid antibodies
![Page 48: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/48.jpg)
![Page 49: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/49.jpg)
![Page 50: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/50.jpg)
OCULAR INVESTIGATIONS
FOLLOWING OCULAR INVESTIGATIONS WERE DONE:
VISUAL FIELD OCT CT SCAN MRI
![Page 51: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/51.jpg)
VISUAL FEILD
• VISUAL FIELD OF BOTH EYES 30-2 HUM PHRY WERE DONE WHICH REVEALS NORMAL VISUAL FIELD IN BOTH EYES.
![Page 52: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/52.jpg)
![Page 53: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/53.jpg)
![Page 54: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/54.jpg)
OPTICAL COHERENCE TOMOGRAPHY(OCT)
SHOWING NORMAL FUNDUS IN BOTH EYES
![Page 55: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/55.jpg)
CT SCAN FINDINGS
![Page 56: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/56.jpg)
CT—CORONAL VIEW(showing thickening of extra ocular muscles)
![Page 57: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/57.jpg)
CT—AXIAL VIEW{showing enlargement of extraocular muscles with sparing of tendon
(fusiform enlargement)}
![Page 58: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/58.jpg)
CT scan– SAGITTAL VIEW(showing enlargement of horizontal extraocular muscles)
![Page 59: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/59.jpg)
MRI ORBIT
• Report verified thickening of extraocular muscles & enlargement of soft tissues.
![Page 60: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/60.jpg)
![Page 61: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/61.jpg)
MRI – ORBIT(axial view)
![Page 62: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/62.jpg)
![Page 63: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/63.jpg)
TREATMENT
![Page 64: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/64.jpg)
TREATMENT
• Patient was prescribed === Anti-thyroid drugs === Symptomatic treatment 2 years back
![Page 65: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/65.jpg)
Conservative treatment• Topical eye drops
== TEARS NATURALE 1 drop 4 times daily
for 2 weeks.
![Page 66: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/66.jpg)
SYMPTOMMATIC TREATMENT
• Tab. BRUFEN (BD) {for pain}
• Tab. ZANTAC (BD) {for stomach upset}
![Page 67: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/67.jpg)
ANTI-THYROID THERAPY
• NEO-MERCAZOLE 5mg
• Tab . Propranolol 1 tab daily
![Page 68: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/68.jpg)
Steroid Therapy for ocular soft tissue inflammation
• Tab. DELTACORTIL 5mg 6- tab in morning 6- tab in evening For 1 week
![Page 69: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/69.jpg)
TREATMENT…. cont..
• Patient took these medications for almost 2 years with tappered dose but he himself discontinued the therapy 1 year back.
• Now he is using topical lubricants only.
![Page 70: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/70.jpg)
FUTURE OPTIONS
• In case, the symptoms persist , treatment option for future include:
• IMMUNOSUPPRESENTS• SURGICAL DECOMPRESSION
OF ORBIT• RADIATION THERAPY
![Page 71: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/71.jpg)
![Page 72: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/72.jpg)
THYROID EYE DISEASE
GRAVE’S OPTHALMOPATHY
![Page 73: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/73.jpg)
INTRODUCTION
![Page 74: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/74.jpg)
INTRODUCTION--THYROID EYE DISEASE
• Seen in 25 – 50% cases of graves disease.• GRAVES DISEASE also known as BASEDOW’S
DISEASE is an autoimmune disorder that usually presents in 3rd to 4th decade of life, affects women more than men, characterized by a triad of features:
• Hyperthyroidism• Diffuse thyroid enlargement• Opthalmopathy
=HYPERTHYROIDISM
=DIFFUSE THYROID ENLARGEMENT
=OPTHALMOPATHY
![Page 75: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/75.jpg)
INTRODUCTION -- TED
• Thyroid eye disease (TED) may occur in the absence of clinical and biochemical evidence of thyroid dysfunction.
• The occurrence of signs of graves disease in a patient who is not clinically hyperthyroid is referred to as euthyroid or ophthalmic graves disease.
• Eye disease may be the first presenting sign of graves disease.
![Page 76: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/76.jpg)
ETIOLOGY
THYROID EYE DISEASE
![Page 77: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/77.jpg)
ETIOLOGY
==GENETIC FACTOR ASSOCIATION: -- HLA DR3, CTLA-4, PTPN22( a T- cell regulatory gene).
==RADIOACTIVE THYROID: Thyroid ablation with orally
ingested radioactive iodine-131 may excerbate
thyroid associated orbitopathy compared with anti-thyroid drugs and surgical ablation.
==AUTOIMMUNE DISEASE ASSOCIATION:
-- Myasthenia gravis, addison disease.
![Page 78: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/78.jpg)
•STRONG ASSOCIATION OF
THYROID EYE DISEASE WITH
SMOKING
![Page 79: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/79.jpg)
PATHOGENESIS
![Page 80: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/80.jpg)
PATHOGENESIS
• This involves an organ specific autoimmune reaction in which a humoral agent (IgG antibody) produces the following changes:
• INFLAMMATION OF EXTRAOCULAR MUSCLES
• INFLAMMATORY CELLULAR INFILTRATION
![Page 81: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/81.jpg)
PATHOGENESIS:INFLAMMATION OF EXTRAOCULAR MUSCLES
• Pleomorphic cellular infiltration, increased secretion of glycosaminoglycans,osmotic retention of water.
• Muscles become enlarge( 8 times their normal size, may compress optic nerve).
• Subsequent degeneration of muscle fibers eventually leads to fibrosis
• Restrictive myopathy and diplopia.
![Page 82: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/82.jpg)
HISTOLOGICAL PICTURE SHOWING ROUND CELL INFILTRATION OF EXTRA OCULAR MUSCLES IN
THYROID EYE DISEASE
![Page 83: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/83.jpg)
PATHOGENESIS:INFLAMMATORY CELLULAR INFILTRATION
Infiltration with lymphocytes, plasma cells, macrophages & mast cells of interstitial fluid, orbital fat & lacrimal glands
Increase in volume of orbital contents
Accumulation of glycosaminoglycans & retention of fluid.
Secondary elevation of intraorbital pressure.
![Page 84: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/84.jpg)
CLINICAL MANIFESTATIONS
![Page 85: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/85.jpg)
CLINICAL MANIFESTATION5 main clinical manifestations of TED are:
1… SOFT TISSUE INVOLVEMENT
(PERIORBITAL & LID SWELLING, CONJUCTIVAL HYPEREMIA.
2...LID RETRACTION3…PROPTOSIS (PASSIVE OR MECHANICAL
PROTRUSION OF EYE BALL)
4…OPTIC NEUROPATHY (SERIOUS COMPLICATION –
COMPRESSION OF OPTIC NERVE MAY LEAD TO VISUAL IMPAIREMENT)
5…RESTRICTIVE MYOPATHY
(OCULAR MOTILTY IS REDUCED INITIALLY BY INFLAMMATORY EDEMA & LATER BY FIBROSIS)
![Page 86: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/86.jpg)
SYMPTOMS
OCULAR SYMPTOMS• DRY EYES• BULGING EYES• DIPLOPIA• VISUAL LOSS• OCULAR PRESSURE OR PAIN• PHOTOPHOBIA• LACRIMATION
SYSTEMIC SYMPTOMS• TACHYCARDIA• NERVOUSNESS• HEAT INTOLERANCE• INCRESE SWEATING• WEIGHT LOSS• IRRATIBILITY• SKELETAL MUSCLE
WEAKNESS
![Page 87: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/87.jpg)
OCULAR SIGNS• VIGOUROUX SIGN( eyelid fullness)• DALRYMPLE SIGN( lid retraction in
primary gaze)• von GRAEFE SIGN( retarted descent
of upper lid at downward gaze• STELLWAG SIGN
( incomplete & infrequent blinking)• GROVE SIGN( resistance to pulling
down the retracted upper lid)• JOFFROY SIGN ( abscent creases in
forehead on sup. gaze)• MOBIUS SIGN( poor convergence)• BALLET SIGN ( restriction of one or
more extra ocular movements)• KOCHER SIGN ( staring & frightened
appearance of eyes)
• PROPTOSIS ( eyes protude beyond orbit…unilateral or bilateral)
• Exophthlmos (appearance of protuding eyes)
• Conjuctival edema• Corneal ulceration• Visual impairement• Visual field defects• Papilloedema• Loss of colour vision• Opthlmoplegia• Optic disc usually normal
![Page 88: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/88.jpg)
SEVERE BILATERAL PROPTOSIS & LID RETRACTION IN THYROID EYE DISEASE
![Page 89: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/89.jpg)
PERIORBITAL SWELLING IN THYROID EYE DISEASE
![Page 90: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/90.jpg)
LEFT EYE SHOW LID RETRACTION &MILD PROPTOSIS
![Page 91: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/91.jpg)
von GRAEFE SIGN( RIGHT EYE)
![Page 92: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/92.jpg)
KOCHER SIGN
![Page 93: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/93.jpg)
RESTRICTED LEFT EYE ABDUCTION
![Page 94: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/94.jpg)
SYSTEMIC SIGNS
• FAST/ IRREGULAR PULSE
• WARM MOIST SKIN• FINE TREMOR• PALMER ERYTHEMA• HAIR LOSS
![Page 95: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/95.jpg)
DIFFERENTIAL DIAGNOSIS
![Page 96: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/96.jpg)
DIFFERENTIAL DIAGNOSIS
• ORBITAL CELLULITIS: Onset of proptosis is earlier & patient has other evidence of infection. (fever)
• IDIOPATHIC ORBITAL INFLAMMATORY DISEASE: More painful than thyroid eye disease.
• OTHER CAUSES OF THICKENED MUSCLES: sarcoidosis, amyloid, acromegaly.
![Page 97: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/97.jpg)
INVESTIGATIONS
![Page 98: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/98.jpg)
INVESTIGATIONS
NON- SPECIFIC• ROUTINE BLOOD PICTURE.• HAEMOGLOBIN.• WBC( total & differential
count.)• ESR.• BLOOD SUGAR.• CHOLESTROL.• URINE EXAMINATION.
SPECIFIC *FOR HYPERTHYROIDISM: == SERUM T3 & T4 LEVEL ==SERUM TSH LEVEL. == THYROID AUTOANTIBODIES *FOR OCULAR MUSCLE ENLARGEMENT: ==PLAIN X-RAY CALDWELL
VIEW(PA view) ==ORBITAL ULTRASOUND ==CT SCAN ORBIT ( AXIAL &
CORONAL VIEW) ==MRI
![Page 99: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/99.jpg)
Axial CT scan showing enlarged extra ocular muscles in thyroid eye disease
![Page 100: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/100.jpg)
TREATMENT
![Page 101: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/101.jpg)
GENERAL MANAGMENTCONTROL OF OCULAR DISCOMFORT=Artificial tears=Topical lubricants=SunglassesADVISE THE PATIENT TO=Avoid smoking as it worsens the prognosis=Avoid dust =Elevate head when sleeping to avoid periorbital edema
![Page 102: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/102.jpg)
MEDICAL MANAGMENTCONTROL OF HYPERTHYROIDISM• Iodine and antithyroid drugs• Radioactive iodineORBITAL DECOMPRESSIONSystemic steroids:• Oral prednisolone: 60-80mg/day (dose should be
tappered after reduction in symptoms)• I/V methylprednisolone: 0.5g in 200ml isotonic
saline over 30 min(may be repeated after 48 hrs)
![Page 103: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/103.jpg)
SURGICAL MANAGMENT
Surgical treatment when there is severe sightthreatening condition or for cosmetic purpose.ORBITAL DECOMPRESSION: (for advanced proptosis & optic nerve compression)
STRABISMUS SURGERY: (to minimize diplopia)
LID LENTHENING SURGERY
![Page 104: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/104.jpg)
OTHER MANAGEMENT OPTIONS
RADIOTHERAPY• ORBITAL RADIOTHERAPY
CAN BE USED TO TREAT OPHTHALMOPLEGIA BUT HAS LITTLE EFFECT ON PROPTOSIS.
• THE RADIATION(1500-2000 Cgy fractioned over 10 days) IS USUALLY ADMINISTERED VIA LATERAL FIELDS WITH POSTERIOR ANGULATION
FUTURE OPTIONS• ANTI-TNF α ANTIBODIES(eg infliximab)
![Page 105: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/105.jpg)
![Page 106: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/106.jpg)
![Page 107: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/107.jpg)
![Page 108: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/108.jpg)
Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease.
![Page 109: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/109.jpg)
• Source• School of Clinical and Experimental Medicine, College
of Medical and Dental Sciences, Institute of Biomedical Research, University of Birmingham, Edgbaston, Birmingham, United Kingdom. [email protected]
• BACKGROUND:• Common autoimmune disorders tend to coexist in the
same subjects and to cluster in families.
![Page 110: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/110.jpg)
METHODS
• A cross-sectional multicenter study of 3286 Caucasian subjects was performed(2791 with Graves' disease; 495 with Hashimoto's thyroiditis) attending UK hospital thyroid clinics to quantify the prevalence of coexisting autoimmune disorders. All subjects completed a structured questionnaire seeking a personal and parental history of common autoimmune disorders, as well as a history of hyperthyroidism or hypothyroidism among parents.
![Page 111: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/111.jpg)
RESULTS
• The frequency of another autoimmune disorder was 9.67% in Graves' disease and 14.3% in Hashimoto's thyroiditis index cases . Rheumatoid arthritis was the most common coexisting autoimmune disorder (found in 3.15% of Graves' disease and 4.24% of Hashimoto's thyroiditis cases). Relative risks of almost all other autoimmune diseases in Graves' disease or Hashimoto's thyroiditis were significantly increased (>10 for pernicious anemia, systemic lupus erythematosus, Addison's disease, celiac disease, and vitiligo). There was relative "clustering" of Graves' disease in the index case with parental hyperthyroidism and of Hashimoto's thyroiditis in the index case with parental hypothyroidism. Relative risks for most other coexisting autoimmune disorders were markedly increased among parents of index cases.
![Page 112: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/112.jpg)
CONCLUSION:
• This is one of the largest studies to date to quantify the risk of diagnosis of coexisting autoimmune diseases in more than 3000 index cases with well-characterized Graves' disease or Hashimoto's thyroiditis. These risks highlight the importance of screening for other autoimmune diagnoses if subjects with autoimmune thyroid disease present with new or nonspecific symptoms.
![Page 113: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/113.jpg)
References • Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a
community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7:481–493
• Barker JM. Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab. 2006;91:1210–1217
• Tait KF, Marshall T, Berman J, et al. Clustering of autoimmune disease in parents of siblings from the type 1 diabetes Warren repository. Diabet Med. 2004;21:358–362
• Laberge G, Mailloux CM, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 2005;18:300–305
• Kasperlik-Zaluska A, Czarnocka B, Czech W. High prevalence of thyroid autoimmunity in idiopathic Addison's disease.Autoimmunity. 1994;18:213–216
![Page 114: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/114.jpg)
![Page 115: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/115.jpg)
prevalence of patients with thyroid eye disease
presenting with apparent unilateral proptosis
![Page 116: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/116.jpg)
• SOURCE:• Orbital Unit of the Department of Visual Science of the
University of Naples “Federico II”• AIMS & OBJECTIVES:• The purpose of this retrospective follow-up study is to
evaluate the prevalence of patients with thyroid eye disease presenting with apparent unilateral proptosis and determine the occurrence of exophthalmos in contralateral non-proptotic eye over the time. Associated features with this event were evaluated.
![Page 117: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/117.jpg)
Methods
• A cohort of 655 consecutive patients affected by thyroid eye disease with a minimum follow-up of 10 years was reviewed. Exophthalmos was assessed by using both Hertel exophthalmometer and computed tomography (CT). The influence of age, gender, hormonal status and of different therapies such as corticosteroids, radiotherapy and surgical decompression on this disease progression was evaluated.
![Page 118: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/118.jpg)
Results• A total of 89 patients (13.5%) had clinical
evidence of unilateral exophthalmos at the first visit. Among these, 13 patients (14%) developed subsequent contralateral exophthalmos. The increase of protrusion ranged from 2 to 7 mm (mean of 4.2). The time of onset varied from 6 months to 7 years (mean time: 29 months). Smoking status, young age and surgical decompression are significantly associated with development of contralateral proptosis .
![Page 119: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/119.jpg)
Conclusions
• Asymmetric thyroid eye disease with the appearance of unilateral exophthalmos at the initial examination is a fairly frequent event, while subsequent contralateral proptosis occurs less commonly. However, physicians should be aware that young patients, particularly if smokers, undergoing orbital decompression in one eye may need further surgery on contralateral side over time.
![Page 120: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/120.jpg)
• References• Burch HB, Wartofsky L: Graves’ ophthalmopathy: current concepts regarding pathogenesis
and management.
• Hales IB, Rundle FF: Ocular changes in Graves' disease: a long-term follow-up study.• Q J Med 1960, 29:113.
• Gerding MN, Terwee CB, Dekker FW: Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.
• Thyroid 1997, 7:885-889.
• Bahn RS, Heufelder AE: Pathogenesis of Graves’ ophthalmopathy.• N Engl J Med 1993, 329:1468-1475.
• Gorman CA: Pathogenesis of Graves’ ophthalmopathy.• Thyroid 1994, 4:
• Heufelder AE: Pathogenesis of Graves’ ophthalmopathy: recent controversies and progress.• Eur J Endocrinol 1995, 132:
![Page 121: CLINICOPATHOLOGICAL CONFERENCE ON Thyroid eye disease](https://reader033.vdocuments.site/reader033/viewer/2022050805/556afc09d8b42a2a4f8b4c5d/html5/thumbnails/121.jpg)